Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.